FibroGen, Inc. Reports FG-4539, HIF-PH Inhibitor, Is Neuroprotective And Significantly Reduces Brain Tissue Damage In Preclinical Model Of Ischemic Stroke

KISSIMMEE, Fla.--(BUSINESS WIRE)--Feb. 17, 2006--FibroGen, Inc., today announced that a single dose of FG-4539, its novel small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) in development for the treatment of ischemic disease, was neuroprotective and significantly reduced brain tissue damage in a preclinical model of permanent ischemic stroke. The potency of FG-4539 and the window of therapeutic opportunity observed following permanent middle cerebral artery occlusion (pMCAO) compare favorably to results from this model reported for the most promising neuroprotective therapies currently in development. The data were presented today at the International Stroke Conference 2006 (Abstract # 427).

Back to news